vimarsana.com
Home
Live Updates
Risankizumab Achieves Primary Endpoints over Ustekinumab in SEQUENCE Trial : comparemela.com
Risankizumab Achieves Primary Endpoints over Ustekinumab in SEQUENCE Trial
Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.
Related Keywords
Laurent Peyrin Biroulet ,
Roopal Thakkar ,
Nancy University Hospital ,
Image Analysis Group Laurent Peyrin Biroulet ,
Infinity Institute ,
Image Analysis Group ,
United European Gastroenterology Week ,
Nancy University ,
Risankizumab ,
Bustekinumab ,
Clinical Remission ,
Clinical Response ,
Endoscopic Remission ,
Endoscopic Response ,
Cd ,
Crohn Disease ,
Crohn X27s Disease ,
Ibd ,
Inflammatory Bowel Disease ,
Skyrizi ,
Stelara ,
comparemela.com © 2020. All Rights Reserved.